Wolverine Asset Management’s Starling Oncology Warrant STLNW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $22.8K | Buy |
467,099
+48,885
| +12% | +$2.4K | ﹤0.01% | 1411 |
|
|
2026
Q2 | $17.1K | Buy |
418,214
+232,777
| +126% | +$11.1K | ﹤0.01% | 1381 |
|
|
2026
Q1 | $8.12K | Buy |
185,437
+4,145
| +2% | +$399 | ﹤0.01% | 1443 |
|
|
2025
Q4 | $21.8K | Sell |
181,292
-15,727
| -8% | -$2.54K | ﹤0.01% | 1361 |
|
|
2025
Q3 | $23.6K | Buy |
197,019
+5,454
| +3% | +$622 | ﹤0.01% | 1282 |
|
|
2025
Q2 | $9.8K | Buy |
191,565
+119,249
| +165% | +$7.56K | ﹤0.01% | 1378 |
|
|
2025
Q1 | $1.96K | Sell |
72,316
-2,404
| -3% | -$62 | ﹤0.01% | 1430 |
|
|
2024
Q4 | $388 | Hold |
74,720
| – | – | ﹤0.01% | 1552 |
|
|
2024
Q3 | $1.49K | Hold |
74,720
| – | – | ﹤0.01% | 1491 |
|
|
2024
Q2 | $1.96K | Buy |
74,720
+20,150
| +37% | +$1.55K | ﹤0.01% | 1495 |
|
|
2024
Q1 | $10.9K | Sell |
54,570
-11,539
| -17% | -$2.63K | ﹤0.01% | 1280 |
|
|
2023
Q4 | $13.2K | Sell |
66,109
-11,789
| -15% | -$1.86K | ﹤0.01% | 1359 |
|
|
2023
Q3 | $7.16K | Sell |
77,898
-5,644
| -7% | -$459 | ﹤0.01% | 1521 |
|
|
2023
Q2 | $2.33K | Buy |
83,542
+200
| +0.2% | +$11 | ﹤0.01% | 1562 |
|
|
2023
Q1 | $5.42K | Sell |
83,342
-10,290
| -11% | -$1.27K | ﹤0.01% | 1535 |
|
|
2022
Q4 | $10.3K | Sell |
93,632
-10,058
| -10% | -$3.28K | ﹤0.01% | 1624 |
|
|
2022
Q3 | $57K | Sell |
103,690
-14,976
| -13% | -$10.4K | ﹤0.01% | 1565 |
|
|
2022
Q2 | $59K | Buy |
118,666
+26,700
| +29% | +$24.6K | ﹤0.01% | 1525 |
|
|
2022
Q1 | $105K | Sell |
91,966
-21,320
| -19% | -$19.4K | ﹤0.01% | 1295 |
|
|
2021
Q4 | $78K | Buy |
+113,286
| New | +$140K | ﹤0.01% | 1424 |
|
Wolverine Asset Management's STLNW Position: Q3 2026 in Review
Wolverine Asset Management increased its Starling Oncology Warrant (STLNW) stake by 12% in Q3 2026, buying an estimated $2.4K and bringing the position to 467,099 shares worth $22.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1411.
Wolverine Asset Management first reported a position in STLNW in Q4 2021 and has held it in 20 quarters since. The position peaked at $105K in Q1 2022. 1 fund tracked by Wall St. Rank holds STLNW as of Q3 2026.
- Wolverine Asset Management held 467,099 shares of Starling Oncology Warrant worth $22.8K as of Q3 2026.
- Wolverine Asset Management bought 48,885 Starling Oncology Warrant shares in Q3 2026, an estimated $2.4K.
- Starling Oncology Warrant made up ﹤0.01% of Wolverine Asset Management's portfolio in Q3 2026, its #1411 holding.
- Wolverine Asset Management first reported a position in Starling Oncology Warrant in Q4 2021 and has held it in 20 quarters since.
- Wolverine Asset Management's Starling Oncology Warrant position peaked at $105K in Q1 2022.
- 1 fund tracked by Wall St. Rank held Starling Oncology Warrant as of Q3 2026.
Based on Wolverine Asset Management's 13F filing for Q3 2026, filed 2 Nov 2026.